Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

Completed · Phase 2

Conditions studied: β-thalassemia, Ineffective Erythropoiesis, Chronic Anemia

In brief

This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment in β-thalassemia.

Key facts

Study ID
NCT03802201
Run by
Protagonist Therapeutics, Inc.
People needed
63
Starts
2018-12-19
Expected to finish
2020-07-31
Last updated by the study team
2021-07-16

Who can join

Age: 12 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.